HCPLive

FDA Approves Ravicti for Urea Cycle Disorders

 
FDA Approves Ravicti for Urea Cycle DisordersFRIDAY, Feb. 1 (HealthDay News) -- Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.

These inherited conditions involve a lack of enzymes that help the body remove ammonia from the blood. In people with UCDs, ammonia build-up can lead to coma, brain damage, or death, the FDA said Friday in a news release.

Ravicti is a liquid taken three times daily with meals. It's been approved for people whose disorders cannot be managed by a protein-restricted diet or amino acid supplements alone, the agency said.

Ravicti was compared to another UCD drug in a clinical study involving 44 adults. The most common side effects of the new drug were diarrhea, flatulence, and headache.

Ravicti is marketed by Hyperion Therapeutics, based in San Francisco.
 

More Information

Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

Fred Lublin, MD, and Patricia K. Coyle, MD, discuss key issues regarding family planning, pregnancy, and disease-modifying therapies in patients with multiple sclerosis.
The field of medical technology is constantly expanding and changing requiring new equipment to be used in a variety of ways. That effort has been brought under one roof at Massachusetts General Hospital thanks in part to the efforts of one generous and appreciative patient.
A cardiovascular disease risk equation has been developed that can be recalibrated for application in different countries, according to a report published online March 25 in The Lancet Diabetes & Endocrinology.

Exposure to common air pollutants before birth may make children more likely to have the symptoms of attention-deficit/hyperactivity disorder (ADHD) and other thinking and behavioral problems, a small new study suggests. The findings were published online March 25 in JAMA Psychiatry.

$vAR$